Podcasts about dna rna

DITCH YOUR DOCTOR! https://www.livelongerformula.com/wam Get a natural health practitioner and work with Christian Yordanov! Mention WAM and get a FREE masterclass! You will ALSO get a FREE metabolic function assessment! HELP SUPPORT US AS WE DOCUMENT HISTORY HERE: https://gogetfunding.com/help-wam-cover-history/ GET NON-MRNA FREEZE DRIED MEAT HERE: https://wambeef.com/ Use code WAMBEEF to save 20%! GET HEIRLOOM SEEDS & NON GMO SURVIVAL FOOD HERE: https://heavensharvest.com/ USE Code WAM to save 5% plus free shipping! GET YOUR APRICOT SEEDS at the life-saving Richardson Nutritional Center HERE: https://rncstore.com/r?id=bg8qc1 Use code JOSH to save money! Josh Sigurdson reports on the mass depopulation event happening now as most sit on their hands distracted. In this video, we delve into a plethora of stories happening simultaneously that you may or may not have already heard of. The Bird Flu hoax continues to be pushed harder by the day with mRNA shots being speedily approved. They're giving pigs genere therapy to allegedly help their hearts as the food supply is poisoned by injection and nanotechnology. Immune Modulation with oral DNA/RNA nanoparticles are being promoted as a "miracle" cure as governments look to new ways they can force inject people by spraying the skies or poisoning the food supply. Cancer mRNA vaccines are being pushed by people like President Trump as doctors warn it goes straight to the heart and causes heart failure. Cellphone radiation is once again being linked directly to cancer following recent studies. Another child has died after 12 cardiac arrests, this time a child actor named Millena Brandão. Many are pointing to the obvious pattern. Studies are coming our regarding SIDS which show that 78% of cases occur within the first week following the injection. Chemicals in food packaging, IV bags are being linked to 356,000 deaths a year from heart disease. Use of antibiotics on factory fsrms are being liked to millions of deaths per year. In Oregon, children are being told not to go outside due to air pollution, though this seems similar to past events where the skies were sprayed with toxins. A Marburg vaccine trial has launched in the United States. Gene edited bananas are hitting the supermarket shelves in the UK. This and much more is examined as these studies and recent stories come out within just 2 weeks! Stay tuned for more from WAM! Get local, healthy, pasture raised meat delivered to your door here: https://wildpastures.com/promos/save-20-for-life/bonus15?oid=6&affid=321 USE THE LINK & get 20% off for life and $15 off your first box! SIGN UP FOR HOMESTEADING COURSES NOW: https://freedomfarmers.com/link/17150/ Get Prepared & Start The Move Towards Real Independence With Curtis Stone's Courses! GET YOUR WAV WATCH HERE: https://buy.wavwatch.com/WAM Use Code WAM to save $100 and purchase amazing healing frequency technology! GET ORGANIC CHAGA MUSHROOMS HERE: https://alaskachaga.com/wam Use code WAM to save money! See shop for a wide range of products! GET AMAZING MEAT STICKS HERE: https://4db671-1e.myshopify.com/discount/WAM?rfsn=8425577.918561&utm_source=refersion&utm_medium=affiliate&utm_campaign=8425577.918561 USE CODE WAM TO SAVE MONEY! GET YOUR FREEDOM KELLY KETTLE KIT HERE: https://patriotprepared.com/shop/freedom-kettle/ Use Code WAM and enjoy many solutions for the outdoors in the face of the impending reset! BUY GOLD HERE: https://firstnationalbullion.com/schedule-consult/ PayPal: ancientwonderstelevision@gmail.com FIND OUR CoinTree page here: https://cointr.ee/joshsigurdson JOIN US on SubscribeStar here: https://www.subscribestar.com/world-alternative-media For subscriber only content! Pledge here! Just a dollar a month can help us alive! https://www.patreon.com/user?u=2652072&ty=h&u=2652072 BITCOIN ADDRESS: 18d1WEnYYhBRgZVbeyLr6UfiJhrQygcgNU World Alternative Media 2025

Imagine a future where we can be individually identified and maintained through frequency-based biomarkers that keep us healthy and emotionally balanced. Sharry Edwards' pioneering work at the Institute of BioAcoustic Biology demonstrates that we can control these frequencies through mind management or programmable devices. Using Vocal Profiling, both emotional and physiological issues can be revealed and addressed, as people with similar health challenges share nearly identical vocal anomalies.Edwards bridges ancient knowledge with modern harmonic theories to establish math as a foundation for wellness. Through frequency entrainment of the brain, the body can be programmed to support optimal function. Her research provides crucial insights into how string theory's infinitesimal vibrations transform into our physical reality, showing how the brain's frequency-based communication can reveal DNA/RNA templates with the potential to extend life.Sharry Edwards stands among the few modern keepers of profound mysteries, bringing forth secrets long hidden from humanity. Her groundbreaking work suggests that at our core, we are sophisticated math-based beings that can be "managed" through individual frequency signatures. She will likely be remembered for her extraordinary ability to bridge the ancient, esoteric, and scientific realms, answering fundamental questions about our origins and potential, while revealing whether frequency represents our medicine of the future or an ancient mystery finally uncovered.Sharry Edwards, the pioneering researcher who has dedicated over 30 years to the study of Human BioAcoustic Biology. At her Institute of BioAcoustic Biology in Albany, Ohio, Edwards and her team at Sound Health are using voice analysis and frequency applications to address a remarkable range of health challenges—from macular degeneration and multiple sclerosis to brain trauma, muscular issues, and nutritional imbalances.Links for the show:The Muscle-Fat Storage Map w/ article Information on how to do your own vocal printsFurther information on Bioacoustics Information on the Sound Health Portal & Free Campaigns •Please sign up for the email list for future notifications•If you would like help starting your own show or podcast, as well as help selecting a microphone and setup for your voice; Please tap the microphone and leave me a message with your contact information and I will get back to you.Or you can email talktomeguy@gmail.com

Imagine a future where we can be individually identified and maintained through frequency-based biomarkers that keep us healthy and emotionally balanced. Sharry Edwards' pioneering work at the Institute of BioAcoustic Biology demonstrates that we can control these frequencies through mind management or programmable devices. Using Vocal Profiling, both emotional and physiological issues can be revealed and addressed, as people with similar health challenges share nearly identical vocal anomalies.Edwards bridges ancient knowledge with modern harmonic theories to establish math as a foundation for wellness. Through frequency entrainment of the brain, the body can be programmed to support optimal function. Her research provides crucial insights into how string theory's infinitesimal vibrations transform into our physical reality, showing how the brain's frequency-based communication can reveal DNA/RNA templates with the potential to extend life.Sharry Edwards stands among the few modern keepers of profound mysteries, bringing forth secrets long hidden from humanity. Her groundbreaking work suggests that at our core, we are sophisticated math-based beings that can be "managed" through individual frequency signatures. She will likely be remembered for her extraordinary ability to bridge the ancient, esoteric, and scientific realms, answering fundamental questions about our origins and potential, while revealing whether frequency represents our medicine of the future or an ancient mystery finally uncovered.Sharry Edwards, the pioneering researcher who has dedicated over 30 years to the study of Human BioAcoustic Biology. At her Institute of BioAcoustic Biology in Albany, Ohio, Edwards and her team at Sound Health are using voice analysis and frequency applications to address a remarkable range of health challenges—from macular degeneration and multiple sclerosis to brain trauma, muscular issues, and nutritional imbalances.Links for the show: The Muscle-Fat Storage Map w/ article Information on how to do your own vocal printsFurther information on Bioacoustics Information on the Sound Health Portal & Free Campaigns •Please sign up for the email list for future notifications•If you would like help starting your own show or podcast, as well as help selecting a microphone and setup for your voice; Please tap the microphone and leave me a message with your contact information and I will get back to you.Or you can email talktomeguy@gmail.com

책에 관한 걸쭉하고 상큼한 이야기 "책.걸.상" 지난 시간에 이어 송기원 생화학과 교수의 'RNA 입문서' 질문 폭발하는 JYP의 모습! 지금 바로 책걸상에서 만나보시죠!

책에 관한 걸쭉하고 상큼한 이야기 "책.걸.상" 코로나19가 재유행 하고있는 요즘! 우리가 꼭 알아야 하는 지식을 담은 송기원 생화학과 교수의 'RNA 입문서' 지금 바로 책걸상에서 만나보시죠!

'விதை' 'வி'யப்பூட்டும் 'தை'யலாகும் தொடர் 'சதை' 'ச'த்தினை 'தை'க்கும். இயற்கை மொழி முறை (NI) - 2. விதை "வினையினை தைத்தல்" என்போம். 'வியப்பூட்டும் தையலாகி' விதை காய் கனிந்து பழமாகிறது. வாய்மொழி கண்ட மனித இனத்தொடர் தாய்மொழி கற்றலில் நிறைவினை தொடர்ந்து பெறுகிறது. 'இயற்கை மொழி முறை(NLP) அச்சில் செயல்படும் அலை வீச்சு('Wave'). தாய்மொழி இயற்கை மொழி முறை ஒலிப்பியலில் கிட்டத்தட்ட 724 ஆண்டுகளுக்கு முன்பு இருந்தே, ஒருவரின் குணம், பரம்பரை உள்ளார்ந்த மனித இன உறுப்புகளில் பிறப்பில் ஒவ்வொரு தலைமுறை கூற்றினிலும், பதிவிலும் நிலைத்து நிற்கிறது. 624 ஆண்டு கால ஆரம்பத்தில் இருந்தே இயற்கை தரும் கொடைதனில் உள்ளவற்றை தொழில்நுட்ப அணுகு முறைகளின் மூலம் நேரடி பயன்பாட்டினை தொடர்ந்து பதிந்து வருகின்றனர். 524 ஆண்டுகளின் பிற்பகுதியில் இருந்து "தலைமுறை தலைமுறை ஆக , அறிவாற்றல் பிறக்கும் போதிலிருந்து பதிவில் நிலை பெற்று மனநிறைவுடன் தாய்மொழி கற்றலிலும் நிறைவை அடைகின்றது." மனித இனத்தொடர்பே தானியங்கும் இயற்கை மொழி முறைமை ஆகும். இயற்கை மொழி செயலாக்க கருவித் தொடர்பு சொல்லாக்கம் : COMPUTER - கணினி DIGITAL - எணினி Syntax - தொடரமைப்பு NLP- செய்நிரல் இயற்கை மொழி செயலாக்கம் (NLP) உரை மற்றும் பேச்சுத் தரவை முழுமையாகவும் திறமையாகவும் பகுப்பாய்வு செய்ய முக்கியமானது. இது அன்றாட உரையாடல்களில் பொதுவான பேச்சு வழக்கில் (SLANG) மற்றும் இலக்கண முறைகேடுகளில் உள்ள வேறுபாடுகள் மூலம் செயல்பட முடியும். ஜாவா மற்றும் ஆர் போன்ற மொழிகள் இயற்கையான மொழி செயலாக்கத்திற்கு பயன்படுத்தப்பட்டாலும், பைதான் அதன் எண்ணற்ற நூலகங்கள், எளிமையான தொடரியல் மற்றும் பிற நிரலாக்க மொழிகளுடன் எளிதாக ஒருங்கிணைக்கும் திறன் ஆகியவற்றால் விரும்பப்படுகிறது. அந்தாதி எதுகை - வாய்மொழி பாவினம் 2- தமிழ் மொழி முறை வாய்மொழி போற்றும் தாய்மொழி ஆளும். பொங்கும் கடல் ஒளியின் வேகம் எங்கும் வீசும் கதிரவனின் வீச்சு தங்கும் உயிரக காற்று மண்டலம் பங்கு கொள்ள தரும் காலம். காலம் கடக்கும் கணிப்பு முறை ஞாலம் போற்றும் வகை உண்டு ஓலமிடும் தடை இயல் வெப்பம் நலமாக இருக்க நிலை பெறும். பெறுபவை நிலைப்பில் தருபவை இருப்பு வேறுபடும் தாயனை(DNA) ஆறுதலில் உயிர்ப்பு அறுசுவை உணவு ஆறனைத் தொடர் (RNA) மாறுபடும் தன்மை வெளிப்புறத் தோற்றம். தோற்றம் யாவும் ஒன்றும் மூலம் தேற்றம் நல்ல நாளது சிறப்பு பற்றும் பொருள் பாசத் தொடர் வற்றாத கடல் சுற்றும் புவி.

14,50,000 இலட்சம் ஆண்டுகளுக்கு முன்பு உயிரிகளை தின்ற காலம் எனப்பதிந்து உள்ளனர். **உயிரக காடி தாயனை(DNA) இணைவு** **ஆயிரமாயிரம் ஆறனை(RNA) தொடர்பு.** **வான் சிறப்பில் பெறும் துடிப்பு** **தான் என்றொரு தருணத்தில் கரு** **இன்சொல் பேசி நன்னெறி சேர்க்கும்** **பன்முக ஆற்றல் இயற்கை முறை.** **தலை முதல் கால் வரை** **இலை மறை காய் தொடர்பு** **மலை முகடு பள்ளத்தாக்கு பகுதி** **அலை அலையான தொடரில் கண்டனர்.** **கண் காது மூக்கு வாய் மெய்** **அண்மை அருமை செல்லும் செல்** **உண்மையில் உயிர் தாங்கும் வாய்ப்பு** **ஆண்மை பெண்மை கலந்த உயிரணு.** **உயிரணு உருவாகி அருகருகே தொடராக்கம்** **பெயரளவில் அறிந்து முறைமை கொள்வோம்** **ஓயாத வழி யாவும் பகிர்வு** **உயிரின அணுக்கருவினில் தாயனை ஆறனை.**

I speak with world expert on deuterium depletion and cancer, Dr Gabor Somylai, from Hungary. He has dedicated his professional life to understanding and treating cancer using by reducing the concentration of the heavy hydrogen isotope, deuterium, in the body. This involves drinking deuterium-depleted water adopting a very high animal fat ketogenic style diet.Deuterium depletion isn't some fringe or whacky alternative healing modality, rather its thoroughly researched topic with decades of benchside and clinical evidence of efficacy (see links below). The concept is understandable when we step of the DNA/RNA/genetic view of cancer and into a mitochondrial metabolic and bioenergetic model. For those who are new the concept of deuterium as it relates to biology and health, check out my earlier episodes with Dr Jalal Khan, Dr Sara Pugh and Dr Laszlo Boros. --------------------------------------------------------------Download my FREE Guide to the Carnivore Diet

Greetings, Pharaohradio family! It's ya boy Jayratedr and in this special podcast session - Jayratedr will be bringing the noise of Truth, sounding the conscious and spiritual alarms of the Most High to all people of all walks of life! The Wiles Of the devil are broad and globally-wide! We, as Children of the light/day of Christ, are NOT to partake in the unfruitful works of darkness but are to reprove (expose/correct) it. Stay tuned in as Jay reveals these hidden revelations in full completion. #Pharaohradio #BiblicalScriotures #EsotericTeachings #DarkOccultRevealed | Email: Jayratedr@Pharaohradio.com | Cashapp: $Pharaohradio | www.blueletterbible.org - www.biblehub.com | Hebrew word :::ABBA::: - https://himpublications.com/blog/meaning-abba/ --- Send in a voice message: https://podcasters.spotify.com/pod/show/larry-holloway-jr/message Support this podcast: https://podcasters.spotify.com/pod/show/larry-holloway-jr/support

Sind wir doch mehr "Eins" mit unserer Umwelt, als wir dachten? Muss ich Angst haben, selbst ein Schwein zu werden, wenn ich Schwein esse, und was hat das eigentlich mit der neuen Impftechnologie zu tun?

It's no bigger than Mars bar, but a device called the MinION could prove vital in the fight against the next pandemic. The MinION – a DNA/RNA sequencer – has already been deployed in the battle against Ebola and was crucial in helping to identify mutations of Covid-19. We speak to Gordon Sanghera, CEO of Oxford Nanopore Technologies, which developed the ground-breaking device, to find out more about how it could help change the future of medicine. RUNNING ORDER: 00:20 - Part One: Ebola and MinION: the making of ONT 03:35 - Part two: Nanopore sequencing and what it means for medicine 12:14 - Part three: ethics, regulation and the future for nanopore tech NEW EPISODES: The Investor Download is available every Thursday and will be released at 1700 UK time. You can subscribe via Podbean or use this feed URL (https://schroders.podbean.com/feed.xml) in Apple Podcasts and other podcast players. GET IN TOUCH: mailto: Schroderspodcasts@schroders.com find us on Facebook send us a tweet: @Schroders using #investordownload READ MORE: Schroders.com/insights LISTEN TO MORE: schroders.com/theinvestordownload Important information. This information is not an offer, solicitation or recommendation to buy or sell any financial instrument or to adopt any investment strategy. Any data has been sourced by us and is provided without any warranties of any kind. It should be independently verified before further publication or use. Third party data is owned or licenced by the data provider and may not be reproduced, extracted or used for any other purpose without the data provider's consent. Neither we, nor the data provider, will have any liability in connection with the third party data. Reliance should not be placed on any views or information in the material when taking individual investment and/or strategic decisions. Any references to securities, sectors, regions and/or countries are for illustrative purposes only. The views and opinions contained herein are those of individual to whom they are attributed, and may not necessarily represent views expressed or reflected in other communications, strategies or funds. The value of investments and the income from them may go down as well as up and investors may not get back the amounts originally invested. Exchange rate changes may cause the value of any overseas investments to rise or fall. Past Performance is not a guide to future performance and may not be repeated. The forecasts included should not be relied upon, are not guaranteed and are provided only as at the date of issue. Our forecasts are based on our own assumptions which may change. Issued by Schroder Investment Management Limited, 1 London Wall Place, London EC2Y 5AU. Registered No. 1893220 England. Authorised and regulated by the Financial Conduct Authority.

JCO PO authors Dr. Michael J. Kelley and Dr. Katherine I. Zhou share insights into their JCO PO article, “Real-world Experience With Neurotrophic Tyrosine Receptor Kinase Fusion–positive Tumors and Tropomyosin Receptor Kinase Inhibitors in Veterans.” Host Dr. Rafeh Naqash, Dr. Kelley, and Dr. Zhou discuss the robust Veterans Affairs (VA) National Precision Oncology Program (NPOP), accurate identification of gene fusions, and toxicities landscape of TRK inhibitors. Click here to read the article! TRANSCRIPT Dr. Rafeh Naqash: Hello and welcome to JCO Precision Oncology Conversations, where we bring you engaging conversations with authors of clinically relevant and highly significant JCO PO articles. I'm your host, Dr. Rafeh Naqash, Social Media Editor for JCO Precision Oncology, and assistant professor at the OU Stephenson Cancer Center in the Division of Medical Oncology.   Today, I'm thrilled to be joined by Dr. Michael J. Kelley. Dr. Kelley is the executive director of Oncology for the Department of Veterans Affairs. He's also the chief of Hematology-Oncology at the Durham VA Medical Center, and also a Professor of Medicine at the Duke University School of Medicine. And he's also a member of the Duke Cancer Institute. We are also joined by Dr. Katherine I. Zhou who is a Hematology-Oncology fellow at the Duke University. Dr. Zhou also spent time at the Duke Medical Center as part of her fellowship training, which I believe is how this project that was led by her came to fruition.  So thank you both for joining today. This is going to be, hopefully, of very high interest to our listeners and I look forward to chatting with you both. Dr. Michael Kelley: Great, thanks for having us. Dr. Katherine Zhou: Thank you for having us. Dr. Rafeh Naqash: Thank you so much for joining. So I was very intrigued with this paper, and this paper follows a recent podcast that we had with Dr. Alexander Drilon, who's led some of the NTRK tropomyosin receptor kinase inhibitor studies that have been published in the last several years. And we had a very interesting discussion a couple of weeks back and I felt this was going to be a very interesting subsequent discussion into what was also an interesting discussion with Dr. Drilon. So what caught my attention is obviously the fact that you guys in this report, which is a real-world report, did not exactly see what we generally expect from clinical trials as far as response to target therapies in NTRK fusions.  So before I ask you questions related to this project, one of the very interesting things at least I found was the fact is that the Veterans Health Administration is the largest integrated health system. Studies, whether conducted in the UK, for that matter European countries, or in Canada, they have integrated health systems which we do not. But we do have this advantage of the VA trying to do things in a very unique, centralized manner. So I wanted to ask Dr. Kelley first, how is it that you have implemented this National Precision Oncology Program, the NPOP as you call it, into the VA precision medicine workflow and how does it help in conducting research studies like the one that you published in the JCO Precision Oncology? Dr. Michael Kelley: Yeah, thanks for that question, Dr. Naqash. The NPOP started in 2016 as a national program and right from the beginning it grew out of an effort that was a joint collaboration between both clinical operations in the VA and the Research Office or the Office of Research and Development. It was designed from the very beginning to support discovery, new knowledge generation, and identifying patients for clinical trials in addition to bringing them best-in-class molecular testing and a consultation service.  So it was initially funded out of the Cancer Moonshot 1 in 2016 when President Biden was then Vice President. The VA endorsed the model going forward in 2019 and now it's continued on and grown even bigger, it's expanded both in terms of scope and the complexity of the testing that's been done. So it was offered as services to facilities. They didn't have to do this, but I think they all saw the value of using NPOP to provide this group of services and that's what led to the generation of the robust underlying dataset that Dr. Zhou has used for this paper. Dr. Rafeh Naqash: Definitely. Thank you so much for that explanation. I did not know, and was not well aware, of how robust this program is. So I think it's a great learning opportunity for our listeners to know that a program like this exists. As we all know, there are different platforms, sequencing platforms, that each institution uses, whether it's commercial or whether it's in-house based. But the fact is, until and unless we have big pool datasets like the ones that you have generated or have access to, it's not easy to answer real-world questions.  So first of all, I'd like to congratulate you and the rest of the VA administration to set up a program like this that hopefully is helping in matching the right patients to the right therapies and in clinical trial approvals. Now, before we take a deeper dive into the study that Dr. Zhou led, I did want to ask you, you have access to this amazing centralized platform, what are the kind of sequencing strategies or platforms that you use as part of this program? And is there an incorporation of molecular tumor boards to help understand some of these sequencing results that sometimes can be a little complicated to understand even for oncologists who look at these reports on a daily basis? So could you tell us a little bit more about that, Dr. Kelley? Dr. Michael Kelley: Yeah, certainly. So the VA contracts for the sequencing service, currently we're contracting with Foundation Medicine and Tempus for the comprehensive genomic profiling. There are some other services, and before we started using Foundation, there were two other companies that we used. There is a molecular tumor board. Our molecular oncology tumor board is designed primarily for case-based education. But there's also an asynchronous on-demand consultation service that occurs electronically because we have a unified electronic health record system. So any oncology provider in the country can enter a request through what's called an interfacility consult. It comes to a team, that team vets that, discusses it with the appropriate experts; that includes molecular oncologists, molecular pathologists. A lot of oncology pharmacists have been trained at a course that's at the University of Kentucky.  And we have a lot of experience in doing this since that service was set up in 2016 as well, right from the beginning, because we understood the complexity of the data and the need for every oncologist across our enterprise to have access to the very best interpretation of that.  We also have educational sessions that are integrated into the molecular tumor board time slot we call primers in terms of the underlying science of why you do the interpretations the way you do. And then there's also some additional education that we'll be endeavoring to offer to our staff and our oncologists coming up this year. Dr. Rafeh Naqash: Excellent. It sounds like you definitely have taken this into a very multidisciplinary approach where you're incorporating oncologists, pharmacists, and perhaps even genetic counselors and then, obviously, keeping the patient at the center and trying to find the best possible therapies that are most relevant for that individual.   Now, going to Dr. Zhou's study here. Dr. Zhou, first of all, it's great to see a fellow lead a study and then especially, I think you're our first fellow on the podcast. We've had a lot of different individuals, but we have not had a fellow before. So thanks for coming.  Could you tell us, for our listeners, what drove your interest into NTRK fusions? As we know, they are rare, something that is not commonly seen, and we do have clinical trial data in this space. So what was the idea behind looking at a real-world data set? Did you start out with a hypothesis or were you just interested to see how targeting these fusions in the real-world setting, actually, what kind of results does it lead to? Dr. Katherine Zhou: Yeah, well, first of all, thanks for the question. And I do just want to mention that although I did sort of bring this project to the finish line, it was started by another fellow, Vishal Vashistha. So just wanted to mention that. And I think the interest was really just that NTRK is such a rare fusion and just a difficult one to be able to study, like you said, in the real-world setting. And we have the advantage of having so much data through the VA and through NPOP, specifically. And so having seen such great results with the TRK inhibitors and clinical trials, I think there's this big question of how that translates into the real-world setting. We have the ability to do that with our large patient population. Dr. Rafeh Naqash: Excellent. And again, it's nice to acknowledge the support that you had from the other individual who co-led this study. Now, since you would have, I'm guessing, done most of the analysis here and looked into the whole idea of the kind of results that you saw—and from my understanding, you looked at the entire VA data set and tried to understand first the incidence or frequency of NTRK fusions and also responses to treatment, which I think is the main message—but could you tell us a little bit more about the data set? How did you acquire the data set, and what it took to analyze? Because obviously every project has a very unique story, and I'm guessing there's one very unique story here, since as a fellow you have limited time to do all this interesting work. So how did you navigate that and analyze and work with some of the things that you had to look at to get to the results? Dr. Katherine Zhou: Yeah, so again, this was work that was done with multiple people involved, of course. And we used what we had, the resources we had available, some tools we had available through the VA. So first, looking at NPOP and looking at patients who are sequenced through NPOP, we could just find all the ones who had an NTRK rearrangement of some kind. The second way we went about finding patients was through the CDW or the Corporate Data Warehouse where we could see which patients were prescribed larotrectinib or entrectinib and kind of go backwards from there and see which of those patients had NTRK alterations or specifically NTRK rearrangements. And so we combined the patients from both of those different methods to come up with our cohort at the end of 33 patients with NTRK rearrangements and 12 patients who are treated with TRK inhibitors. Dr. Rafeh Naqash: Excellent. Could you walk us through what was the subsequent analysis as far as how many NTRK fusions? I know you mentioned in the paper about DNA versus RNA-based testing. So how many were DNA-based, how many were RNA-based? I think there's some element of ctDNA-based testing also, or what tumor types those people had so that we get an understanding of what's the landscape of the findings that you had. Dr. Katherine Zhou: Sure. Since this is a real-world setting, as you may expect, the vast majority of the sequencing was done through tissue DNA sequencing, and that was the case. So for the 25 patients who were sequenced through NPOP that we found who had NTRK rearrangements, 23 of them had tissue DNA sequencing. And then one was tissue DNA RNA, and one was cell-free DNA sequencing. And so using that and being able to go back and look at how many patients have been sequenced in NPOP in total, we could kind of come up with a yield, although the numbers are very small. But we do see that there does seem to be probably a lower yield, for example, with cell-free DNA sequencing, as one might expect.  And then looking at our total group of 33 patients, if we look at what types of cancers they had, we did have quite a few patients just based on prevalent tumors at the VA, I think, and in the population, prostate cancer was common, lung cancer, and then we had smaller numbers of colon and bladder, and I think there's a pancreatic cancer patient. We did have some of these rarer tumor types that more commonly have NTRK fusions as well, so like papillary thyroid carcinoma, and salivary gland cancers as well as soft tissue sarcomas. Dr. Rafeh Naqash: Question for you, Dr. Kelley, related to this data set: do you think that given that the denominator that you have is a unique population, the VA population, that's often males, they're usually above the age of 18, could the frequency have been influenced by that denominator where you may not have been able to capture, let's say, some of the rarer tumors that happen in the younger patient population, for that matter? Could that be a little bit of a bias here?  Dr. Michael Kelley: Definitely. The population of veterans that have cancer that is treated in the Veterans Health Administration do represent generally adult males in the United States, but there is some skewing in certain regards. One of them is towards a higher frequency of smoking status. So not current smoking, which is actually about the same as the national average of about 11%, but the former smoking rate is about twice as high as it is in the rest of the United States. So we may have a lower frequency of some actionable variants in cancers in general because there's a higher etiological role for tobacco smoke in our population. But overall, looking at adult men if we look at like EGFR mutations, our incidence of EGFR mutations in adenocarcinoma is similar to what is reported in other real-world evidence bases from the United States, which is significantly lower than that which is found in academic medical centers. Dr. Rafeh Naqash: Thank you. I'm a big fan personally of real-world data sets. I do a lot of this with some other collaborators and generally, I do phase I trials, which is why I'm interested in precision medicine. And two weeks back, actually, I had a patient with prostate cancer, who ended up having NTRK fusion on a liquid biopsy. Now, you do talk about some of this related to in-frame or out-of-frame fusions and how that can have interesting aspects related to the kinase domain functionality and RNA expression. Dr. Zhou, for the sake of our listeners, could you briefly describe why understanding some of that is important and what implications it has? Dr. Katherine Zhou: Yeah, so I think the oncogenic NTRK fusion that we think of and that's being targeted by the TRK inhibitors is a fusion 5-prime of a protein that forms a dimer and on the 3-prime end is the kinase domain of the tropomyosin receptor kinase. And so you have to have some kind of a gene fusion that results in not only the transcription of that RNA fusion, RNA transcript, but then the translation of that fusion protein. So that needs to be, like you mentioned, that has to be in frame so that the entire protein is translated and expressed and it needs to include the kinase domain. It can't be the other end of the NTRK gene. And both of the genes need to be in the same orientation, of course. And then also the partner gene probably matters in that the ones that we know that actually cause activation of this oncogene are the ones that sort of spontaneously dimerize. And so that's a lot of requirements that we don't necessarily see when we just get, for example, a DNA sequencing result that says there's an NTRK rearrangement. Dr. Rafeh Naqash: Excellent way to describe the importance of understanding the functionality of the activated oncogenic fusion. Now, I know here in most of the patients that you have is DNA sequencing and I'm sure you'll talk about some of the results. And when you connect the results to the kind of data that you have, do you think not having the RNA assessment played a role in not knowing perhaps whether those fusions were functionally active?  Dr. Katherine Zhou: Yes, I think we can't know for sure without having the RNA sequencing data. But certainly, that is a pattern in our small number of patients that we saw and something that makes sense just in terms of the mechanism of this oncogenic fusion protein. So I think that is a question of when should we be doing RNA sequencing to confirm that a fusion that we see on DNA sequencing is actually transcribed into RNA and how do we use RNA sequencing in a cost-effective and useful way to be able to detect more of these NTRK fusions that are actually clinically relevant. Dr. Rafeh Naqash: I absolutely agree with you and this is an ongoing debate. I know some platforms, commercial platforms that is, have incorporated RNA sequencing both bulk or whole transcriptome as part of their platform assessments, but it's still not made inroads into some other sequencing platforms that are commercially used. So it's an ongoing debate, but at the same time helping people understand that certain fusions need some level of RNA assessments to understand whether they're functionally active or not. Which again has implications, as you pointed out in terms of therapies are extremely relevant.   Now, going to the results, which again was very interesting, could you tell us about the findings from the therapeutic standpoint that you observed and what your thoughts are about why you saw those results which were very different from what one would have expected?  Dr. Katherine Zhou: Right. So in the clinical trials of larotrectinib and entrectinib, there were quite high objective response rates on the order of 60%, 70%, even almost 80%. In our very small real-world group of 12 patients who were treated with TRK inhibitors, nobody had an objective response and five patients had stable disease and everybody else, the other seven patients, progressed.  And so the question is why did we see such a big difference compared to the trials? I sort of think of this as two big buckets. One is the population that we were looking at. So this is a real-world population. For example, in the clinical trials, there were almost no Black or African American patients, whereas here we had about 30%-40% Black or African American patients.  Because it's a VA population, it was very heavily male, of course, the age groups are also different in that we didn't have children in the VA population whereas children were included in the trials. And the tumor types also differed because I think in the trials, which makes sense, there's a bias towards tumor types that have more NTRK fusions, and some of the tumor types we were looking at are just common tumor types like prostate and lung cancer where NTRK fusions are not common. But just because there are so many patients with these cancers, we did see them. And so certain of these groups, particularly certain racial and ethnic groups as well as certain tumor types, were not really represented in the trial to the extent that we can make conclusions about whether TRK inhibitors are effective in this population. So that's one.  The second part, I think we've already talked about some, is just the method of detecting these NTRK fusions and how many of these NTRK fusions were actually truly producing oncogenic fusion proteins. And I tried to sort of categorize some of these fusions as being canonical in that they've been more studied. We know the partner gene, they are known to produce an oncogenic protein and to respond to TRK inhibitors. But actually of the four patients who had what we called canonical fusions, all four of them had stable disease at least, whereas the ones that were noncanonical mostly did not have a response or have even stable disease and mostly just progressed. And so then you wonder whether they even had the actual target protein we thought we were targeting. So this is where the real-world setting we're not doing the RNA sequencing or this additional testing to confirm that it's an oncogenic fusion protein. Dr. Rafeh Naqash: And I do see in your results there's a patient especially—you pointed out canonical and noncanonical fusions—you have a patient with a papillary thyroid cancer that I believe had a stable disease for close to two years plus. Is there anything interesting apart from an NTRK fusion in that specific patient where certain co-mutation could have played a role or certain other factors that do you think played into the fact that this patient had stable disease but didn't respond on the TRK inhibitor? Dr. Katherine Zhou: I don't have a great answer for that. I think this is one of the cancers that was well represented in the trials and that commonly has NTRK, or more likely has NTRK fusions. And this was a well-studied canonical NTRK fusion. So I think those are all reasons. The question of co-mutations I think is really interesting. We didn't have the data for every single patient, but for the ones we looked at a lot of the time, NTRK fusions are mutually exclusive with other driver mutations. So we didn't see a whole lot of commutations that we could sort of differentiate between responders or stable disease and progression.  Dr. Rafeh Naqash: Thank you. Going to the toxicities, as a phase I trialist myself toxicity is the bane of my existence where we have to label toxicities, attribute toxicities, understand toxicities. The trial, obviously, as you very well know, that in the trials, they didn't have a lot of toxicities that caused patients to come off or required significant dose reductions, which is not the case compared to what you saw. Could you tell us a little bit about the landscape of toxicities for TRK inhibitors and what you saw in your cohort? That, again, I feel was interesting.  Dr. Katherine Zhou: Of the 12 patients, I think two-thirds of them had either dose reduction or interruption or discontinuation, or some combination of the above. The toxicities we saw were more common than, or at least led to discontinuation and interruption and dose reduction more commonly than in the trials. But the toxicities we saw were also seen in the clinical trials. So LFT elevations, creatinine elevations, neurotoxicity, some cytopenias. We didn't actually see a whole lot of that, but those were present as well, and then some sort of nonspecific things like fatigue. And so, as much as we could tell from retrospective trial review, at least these were severe enough to lead to holding the drug. Dr. Rafeh Naqash: Thank you so much, Dr. Zhou. Question for you, Dr. Kelley. Putting this into perspective, the analysis that you did, how would you connect it to other real-world questions that one could answer using these kinds of data sets? So basically, what are the lessons learned from this amazing program that you guys have run successfully and are, I'm guessing, expanding in different directions? And how can you use a program like this to look at some of these unique questions using real-world data sets? Dr. Michael Kelley: There are a couple of, I guess, next steps for us that are based off this study and other information that we've gotten in other analyses from our NPOP data set. So, first of all, access to an RNA-Seq test. So that has been resolved to some extent, in that we now have two options for comprehensive genomic profiling, one of which does have RNA-Seq.  And then the other approach that we're doing is to do more robust data generation. So we're going to be launching a study to collect prospective data on patients who are treated with off-label drugs. And as part of that, we will also have an on-label cohort for rare populations or any investigator in the VA who's interested in a particular drug or a particular genetic variant. They'll be able to tie into this protocol, and we will then collect data from across the system prospectively, which we think will improve the quality to some degree.  And then thirdly, I think there's an opportunity to merge the initial generation of data in rare genetic types or other populations, which are highly selected by doing a distributed type of clinical trial where patients can be enrolled in prospective treatment trials. So we're not just generating data based on their real-world exposure to FDA-approved drugs, but we're generating data as we're developing the new drugs, we can have a much more heterogeneous and representative population of patients enrolled in clinical trials. So this is called the decentralized clinical trial model. We're starting to launch some trials with industry partners in this area to test out the model. If it works, I think we'll be able to help contribute to the knowledge that we all can use in terms of the patient types, the patient characteristics, but also some of the different tumor characteristics, and also to bring clinical trial opportunities to a more representative group. A lot of the initial clinical trials are done in urban areas, rural populations in VA are about a third of our patients live in rural areas, compared to only 14% of the country. So we think this is a very important diversity issue that should be addressed. Those are some of the ways that we're taking a lesson from this trial and other data that we have to sort of bring it forward. Dr. Rafeh Naqash: Those are excellent next steps and I think the kind of work that the VA is doing and this specific program, Precision Oncology Program, the NPOP program is doing, it's definitely setting up a unique standard in the United States where we have been limited by not having a centralized database. So setting something up of this sort hopefully will help answer a lot of these unique, interesting questions as you have access to data. And then the fact that you mentioned decentralized clinical trials and trying to cater to this access issue for patients in the VA system, I think that would be huge.  And again, I congratulate you and your team on these efforts, and once again, thank you for joining us today and making JCO Precision Oncology a destination for your interesting work. We hope to see more of this work subsequently and hopefully, I get a chance to talk to you more about all the exciting stuff that you guys are leading within the VA health system.  Thank you for listening to JCO Precision Oncology Conversations. Don't forget to give us a rating or review and be sure to subscribe so you never miss an episode. You can find all ASCO shows at asco.org/podcast.  The purpose of this podcast is to educate and inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions.   Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Bios: Michael J. Kelley, MD, is Executive Director of Oncology for the Department of Veterans Affairs, Chief of Hematology-Oncology, Durham VA Medical Center, Professor of Medicine at Duke University School of Medicine and Member of the Duke Cancer Institute. Katherine I. Zhou, MD, PhD is a hematology-oncology fellow at Duke University. She also spends time at the Durham VA Medical Center as part of her fellowship training. COIs: Michael J. Kelley, MD Research Funding: Novartis (Inst), Bristol-Myers Squibb (Inst), Regeneron (Inst), Genentech (Inst), EQRx (Inst) Katherine I. Zhou, MD, PhD: No disclosures  

I really want to talk about melasma. When I came into medical dermatology, I was really unfamiliar with it. 10 years later, we know a little more about it as well as some treatment options. There was a patient we were treating at the first practice I worked at who had really bad melasma, and looking back, I can't believe what we were doing. I think a lot of people still don't know the best steps to take. There's a genetic component that is causing people to be more susceptive to melasma, and it's been reported in 41-61% of patients in Brazil. Skin pigmentation really does follow an inheritance pattern. There's also an inflammation component that I don't think we were appreciating until recently. We're now at the point where we can really look at melasma, accept that there's no cure, and determine the best treatment. First of all, sun protection is key, and it should be started early. You should use a physical sunscreen rather than a chemical one, as chemical sunscreens can actually flare parts of the melasma. Hydroquinone is another topical treatment, and it interferes with the melasma genesis. It prohibits DNA/RNA synthesis that alters the formation of melasma. However, hydroquinone can cause some rebound pigmentation in the long-term. Azelaic is another good topical treatment, and it can be used during pregnancy whereas hydroquinone cannot. There are also some oral treatments that need more research, but moving to in-office methods, chemical peels are fantastic. There are also people that will use IPL or BBL lasers, but I never would. It's not a solution, it's a bandaid. We certainly don't have all the answers for treating melasma right now, but some devices are really helping us find good solutions.   Patreon Page: https://www.patreon.com/BeautyCultureTechnique  

Link to bioRxiv paper: http://biorxiv.org/cgi/content/short/2023.04.12.536672v1?rss=1 Authors: Fujiwara, Y., Saito, K., Sun, F., Inoue, E., Schimenti, J., Okada, Y., Handel, M. A. Abstract: An unbiased screen for discovering novel genes for fertility identified the spcar3, spermatocyte arrest 3, mutant phenotype. The spcar3 mutation identified a new allele of the Setx gene, encoding senataxin, a DNA/RNA helicase that regulates transcription termination by resolving DNA/RNA hybrid R-loop structures. Although mutations in the human SETX gene cause neural disorders, Setxspcar3 mutant mice do not show any apparent neural phenotype, but instead exhibit male infertility and female subfertility. Histology of the Setxspcar3 mutant testes revealed absence of spermatids and mature spermatozoa in the seminiferous tubules. Cytological analysis of chromosome spread preparations of the Setxspcar3 mutant spermatocytes revealed normal synapsis, but aberrant DNA damage in the autosomes, and defective formation of the sex body. Furthermore, Setxspcar3 testicular cells exhibited abnormal accumulation of R-loops compared to wild type testicular cells. Transient expression assays identified regions of the senataxin protein required for sub-nuclear localization. Together, these results not only confirm that senataxin is required for normal meiosis and spermatogenesis but also provide a new resource for determination of its role in maintaining R-loop formation and genome integrity. Copy rights belong to original authors. Visit the link for more info Podcast created by Paper Player, LLC

What if you could program a cell directly to fight cancer? What if you could solve the 7,000 genetic diseases facing our species? This type of science fiction is now a reality, thanks to today's guests on the Beat the Often Path Podcast. Joining me today are Omar Abudayyeh and Jonathan Gootenberg, creators of the AbuGoot lab at MIT, two people leading the way in gene therapy, gene editing, and CRISPR innovations. The AbuGoot lab combines natural biological discovery and molecular engineering to develop a suite of new tools for manipulation of DNA, RNA, and cellular states – the cellular engineering toolbox. In short, it doesn't get more cutting edge than this. ➡️ https://www.abugootlab.org/ ➡️ Highlights: https://rosspalmer.com/omar-abudayyeh  

#தாய்மொழி_நாள்_பதிவு_பாடல்** தாய்மொழி நாள் பலரும் நல்கும் உய்ய உயர உயிரிய தொடரிணைப்பு ஆய்ந்து அறிந்த மெய் உறுப்பு வாயீந்து ஒலிக்கும் ஒலி மரபு.** மரபணு படிமாற்றம் தம்மிதழுக்கு உருமாறும் இரண்டடி மூன்றடி முறையாக்கச் சொல் வரலாறு படித்துறை படிமலர்ச்சி உருபன் நரம்பசைவுப் பண் பாடும் பண்பாடு பண்பாடும் பயணத் தொலைவு இருக்கை மண்ணியக்க செயல் பாட்டில் அடங்கும் எண்ணும் குறியீடு மொழியில் சொல் கண்ணும் கருத்தும் நிறைவாக தாயனை. தாயனை(DNA) ஆறனை(RNA) உயிரிய வாழ்வு இயற்கை தரும் தீர்வு நீர்ப்பசை தயவின் தரவு வரலாற்று முதல்படி பயன் தரும் நலமே தாயகம்.

Deeeeep episode..wow

A testimony of an older lady hallucinating snakes and sea creatures after receiving her Pzifer shot. Her experience seems to describe the snake's DNA transfer cellular memory, which is real. Many organ recipients have experienced donor memories and personality changes. I believe that's what she is describing in the video. It confirms that snake DNA/RNA is in the shots.Video posted at: https://www.savedandloved.com/post/terrifying-testimony-of-seeing-snakes-dna-transfer-cellular-memoryMy books are available on my site, https://www.savedandloved.com/shopPlease donate to my site, https://www.savedandloved.com/donate.Please buy me a coffee:https://www.buymeacoffee.com/savedandloved.

In today's episode, our guest is Tom Paladino, a scalar energy researcher with more than 25 years of experience developing techniques to enhance our health and wellness. He shares his passion for changing the world through scalar energy. Tom expresses his excitement because he believes this technology will move us away from electricity and fossil fuels and significantly improve our health. He describes a quantum process of balancing a person's brainwaves or chakras, which he also refers to as scalar energy points. Tom emphasizes that it is beyond physiological healing and invites people to send their photos to their website for free and experience a new level of healing. He hopes that people will open their minds to this new paradigm and expand on the possibilities that Nicolas Tesla presented us many years ago.Who is Tom Paladino?Tom Paladino is a humanitarian who wants to follow in the footsteps of the father of Scalar Energy research or knowledge, Nicola Tesla and change the world. He is a researcher who wants to make a difference starting with giving people the knowledge and tools they need to get back to their best health and improve their quality of life.Tom also studied the work of Hieronymus in scalar energy. Hieronymus is known for his contribution to the field of agriculture, which includes unbinding the DNA/RNA of harmful microbes that were causing trouble in the industry.Tom was fascinated by the existence of this energy that could not be found in the electromagnetic spectrum. This inspired him to learn more about it and then harness scalar energy by developing a tool known as "Scalar Light."Tom is hoping that we will be curious about scalar energy and rediscover it together to bring us to a future that is less dependent on non-renewable energy sources and learn to use scalar light to improve our health and wellness. Check out Tom:Email:  tompaladino101@gmail.com Web: https://www.scalarlight.com/ LinkedIn:  https://www.linkedin.com/in/tompaladinoscalar/ FB:  https://www.facebook.com/experiencescalar YouTube: https://www.youtube.com/user/TomPaladinoScalarIG: https://www.instagram.com/scalarlight/ Connect with Chad:Strategy Call: https://calendly.com/mrtenacity40/pgi-coaching-consultWebsite: https://mrtenacity.com/LinkedIn: https://www.linkedin.com/in/chad-osinga-b62a08b1/FB: https://www.facebook.com/108630534048340IG:https://www.instagram.com/mr._tenacity/TikTok: https://www.tiktok.com/@mrtenacity40

View the Show Notes Page for This Episode Become a Member to Receive Exclusive Content Sign Up to Receive Peter's Weekly Newsletter Max Diehn is a Professor of Radiation Oncology at Stanford and a clinical radiation oncologist specializing in lung cancer. Max's research focuses on developing novel methods for detecting circulating tumor DNA in the blood of cancer patients and on elucidating the molecular pathways and genes associated with cancer. His interests also include uncovering biomarkers that can predict patient survival, responses to therapy, and disease recurrence. In this packed episode, Max discusses the history of blood-based cancer screening and the importance of understanding the predictive value of tests—sensitivity, specificity, negative predictive value, positive predictive value – and how these metrics play into cancer screening. Max then goes in depth on the topic of liquid biopsies, including the history, current landscape, and possible future of liquid biopsies as a cancer detection tool. He discusses how these non-invasive blood tests can detect DNA/RNA from tumor cells released into the blood as well as the different methods one can use to predict if a cancer is present. He gets granular on the topic of cell-free DNA/RNA signature, methylation patterns, and the importance of knowing mutation information, and he ends with a discussion on the exciting future of liquid biopsies and how we can possibly get to the panacea of cancer screening. We discuss: Max's training that planted the seeds for development of liquid biopsies [4:30]; Max's decision to specialize in radiation oncology [11:45]; A culture at Stanford that values research and physician scientists [17:00]; The motivation to develop liquid biopsies [19:15]; History of blood-based cancer screening and understanding the predictive value of tests [25:30]; Current state of lung cancer and the need for better screening [32:45]; Low-dose CT scans: an important tool for managing lung cancer but with limitations [42:00]; Using liquid biopsies to identify circulating tumor cells [47:00]; Liquid biopsy research moves from circulating tumor cells to cell-free DNA [1:03:00]; Zeroing-in on circulating tumor DNA in cell-free DNA [1:10:48]; Cell-free RNA and Max's vision for cancer detection from a blood sample [1:22:00]; Methylation patterns and other informative signatures found in DNA [1:24:30]; Mutation-based methods of liquid biopsies [1:26:30]; Understanding the sensitivity and specificity of a diagnostic test [1:30:30]; Existing clinical liquid biopsy tests and their limitations [1:37:30]; The future of liquid biopsies [1:44:00]; How we get to the panacea of cancer screening [1:52:00]; More. Connect With Peter on Twitter, Instagram, Facebook and YouTube

After experiencing blinding headaches in early August of 2021, Shawn Mahoney's 6 year old  daughter Layla was diagnosed with a High Grade Anaplastic Supertentorial Ependymoma, which is a form of Pediatric Brain Cancer. After her initial surgery on August 2nd of last year Layla had to undergo another surgery just 5 weeks later, followed by 33 rounds of proton therapy, followed by another surgery on March 11th of this year, which finally completely removed her tumor. On May 18th, DNA/RNA sequencing showed that there was an 81.82 chance that her cancer would NOT come back and Layla was able to complete her academic year in school. There have been new developments in her case since this podcast was recorded and they will be talked about on my Outtro. 

1.WHO國際衛生條例突發事件委員會在6月25日開會後，一致建議世衛組織總幹事現階段應確定疫情不構成「國際關注公共衛生緊急事件」（PHEIC，Public Health Emergency of International Concern）。 2.報告中討論了五月以來在47個國家已經有了3040例通報。目前主要在歐美流行的猴痘和在非洲觀察到的病程表現通常不典型，可能僅有少數疹子，侷限在生殖器，鼠蹊部，肛門周圍，而不會到全身。他也可以在發燒，淋巴結腫大，疲勞前就有疹子。 3.多半都是輕症，極少數需要住院。目前僅通報一例免疫不全的患者死亡。似乎致死率也和之前有所改變。病毒有可能突變到比較會傳染，但致死率也降低。起碼不像非洲看到的1%甚至到10%的致死率。 4.一些初步的研究估計此波R0值是0.8，但在高風險族群比方說和患者從事高危險性行為者，則會大於1。荷蘭研究平均潛伏期是8.5天，但可以在4.2到17.3天之間。目前只有10位醫護人員染疫，不過9位都是非職場感染。 5.WHO委員會決定目前不構成國際關注公共衛生緊急事件PHEIC，但需要繼續關注後續發展。如果有以下狀況發生，可能都要重新評估： a.接下來的 21 天內報告的病例大為增長，在目前受影響的人群中和之外，比方說在性工作者中發生的比例。 b.有證據表明在更多國家造成明顯傳播，或在已流行國家還產生了更多傳播。 c.在弱勢群體的病例數量增加，比方說免疫不全族群，包括控制病況不佳的HIV帶原者，孕婦和兒童。 d.若有報告臨床嚴重程度增加的證據，比方說死亡率或是住院率增加。 e.若有證據表明在歐美反向感染到動物。 f.若有證據表明病毒有明顯突變導致其傳染力、致病力或免疫逃逸特性增強，對病毒藥物有抗藥性等等。 g.若在西非和中非國家以外的地方發現致病力更強的病毒株流行的證據。 p.s.PHEIC指的是「通過疾病的國際傳播構成對其他國家的公共衛生風險，以及可能需要採取協調一致的國際應對措施的不同尋常事件」；該事件狀態在「情況嚴重、突然、不尋常或意外」、「公共衛生影響超出了受影響國家的邊界​​」、「可能需要立即採取國際行動」時啟用。 自2009年以來，共計有六次國際關注的突發公共衛生事件，分別是：2009年H1N1新型流感疫情、2014年小兒麻痺疫情、2014年西非伊波拉疫情、2015年至2016年茲卡病毒疫情、2018年至2019年剛果伊波拉疫情，以及於2020年1月31日宣布的2019新型冠狀病毒疫情。 04b解讀： 1.此波猴痘疫情已經超過3000例，八成都在歐洲。多半都有性行為密切接觸史。WHO報告中表示此次病毒有不典型表現，不會像傳統上先發燒然後起疹子，從臉部開始，然後到身體其他部位這樣的病程。這次滿多病患可能僅有少數疹子，甚至只有一顆。他可以侷限在生殖器或是鼠蹊部，肛門周圍，而不會到全身。他也可以在發燒前就有疹子。我個人猜測這樣的不典型表現，似乎代表病毒本身已經有突變了。和之前在非洲看到已經不同。這樣輕症的表現，可能讓這個病較難診斷，且已經在歐美傳播一陣子了。 2.目前僅通報一例奈及利亞案例死亡，似乎致死率也和之前有所改變。病毒有可能突變到比較會傳染，但致死率也降低。起碼不像非洲看到的1%甚至到10%的致死率。 3.目前不是很確定性行為體液是否會傳染。但確定的是透過直接接觸受感染的皮膚疹子是會傳染的。 4.在非洲比較常見的傳染途徑是囓齒類傳染人，但這波歐美疫情顯然主要應該是人傳人，且多半是親密接觸。 5.我個人目前不會特別擔心猴痘，至少威脅不會有新冠病毒高，主要有以下原因： a.目前看來飛沫甚至空氣傳染應該不是主要傳播途徑。不然我們看到的案例數理當更多。且在戴口罩勤洗手的新冠防疫習慣之下，應該不太容易傳播。主要要提醒的是，不要進行不安全的性行為。 b.此疾病已經有疫苗也有藥物。且絕大多數都會自己好。 c.這是DNA病毒，不會像RNA病毒一樣這麼容易突變。 別被新聞嚇到了！我不會理解猴痘為下一個大魔王。新冠對於全人類的威脅目前還是大很多啦。 來複習一下猴痘懶人包。 https://linshibi.com/?p=40187 歡迎追蹤前台大感染科醫師。04b的發聲管道！ 我的電子名片 https://lit.link/linshibi 希望大家當我的種子教師，推廣正確的新冠衛教。科學防疫，不要只以恐懼防疫！ 歡迎贊助林氏璧孔醫師喝咖啡，讓我可以在這個紛亂的時代，繼續分享知識努力做正確新冠相關衛教。 https://pay.firstory.me/user/linshibi Powered by Firstory Hosting

Leann Wolff is a Human Design professional and well-rounded coach who supports her clients in life, business, and building wealth. She supports service-based business owners in creating a scalable business model and stepping away from 1:1 services. By helping her clients create clarity in their lives, she supports them in understanding their natural-born talents, how to use them and harnessing the power of the laws of the universe. Leann is truly passionate about watching her clients reach their ‘aha' moment when they come to the realisation that they can simply be themselves AND create the life they desire- not one or the other. There is amazing power in an individual claiming what they want AND trusting themselves at every turn! The moment you are born, there is a purpose waiting within you- you just need to embrace it to find the life you were meant to live! By focusing on human design, Leann helps her clients decipher and understand the roadmap of their lives written in their DNA/RNA. This blueprint is the KEY to a fulfilling life and a fulfilling career or business plan that is just waiting for you to uncover! Social Media https://www.youtube.com/c/LeannWolff https://www.facebook.com/groups/2444989022424502 https://www.instagram.com/leannwolff_/ https://www.linkedin.com/in/leannwolffpowerofself/ Website https://www.powerofself.ca/ Promotions/ Freebies https://www.powerofself.ca/offers/3n58GiLG --- Send in a voice message: https://podcasters.spotify.com/pod/show/entrepreneurtalks/message

References Dr Guerra's letures/reasoning SCIENCE ADVANCES • 22 May 2019 • Vol 5, Issue 5 Cell MetabolismVolume 22, Issue 2, 4 August 2015, Pages 304-311 Cell Chem Biol. 2020 May 21; 27(5): 538–550.e7. --- Send in a voice message: https://anchor.fm/dr-daniel-j-guerra/message

Tom Paladino is a Scalar Energy Researcher with over 25 years of experience developing healing techniques designed to help people all over the world to recover from pathogenic infections and experience true health and wellness. The story begins back in Tom's undergraduate days when he became inspired by his research into the work of various scientists. Exploring the discoveries and theories of Hieronymus, Moray, Priore, and Nikola Tesla, he was intrigued by the existence of an energy that is not part of the electromagnetic spectrum. Taking this as his inspiration, he dedicated himself to a course of independent study to better understand the possibilities of this unique energy with the ultimate aim of successfully harnessing it. Tom realized that the scalar energy he was studying has been known to many cultures throughout the ages; it may be referred to as prana, chi, radiant energy, zero-point energy, qi, orgone, or eloptic energy. Encouraged by the timeless, all-pervading nature of this fundamental energy source, and after years of experimentation and modification, Tom developed a unique healing technique using scalar energy called Scalar Light that appears to have the ability to transmute pathogens quickly and painlessly. A few highlights from the show: 1. Scalar Light is a remote healing process, which is made possible by scalar energy instruments that harness and transmute instructive energy. 2. Tom only works with photographs. He does not work directly with people in any way. This process prevents barriers to entry. 3. Scalar Light disassembles and eradicates the molecular bonds to the DNA/RNA of over 400,000 species of harmful pathogens, heavy metals, and environmental chemicals. This frees the immune system to restore homeostasis. Follow and learn more about Tom and Scalar Light at: Scalar Light https://www.scalarlight.com/ 15-Day Free Trial Scalar Light YouTube Channel About Me: In 2011, I was diagnosed with Hodgkin's Lymphoma, out of the blue. I did not have any prior health concerns or issues. Fast forward, the dreaded cancer diagnosis opened my eyes, introduced me to my purpose, and lead me to where I am today. As a Cancer Doula, I use my 10-years of experience with cancer to support and guide others diagnosed with cancer. Many people are not familiar with what a cancer doula is. Think of me as a personal health care advocate. Schedule a free 30-minute meet and greet call to learn more. https://bit.ly/OTOSDiscovery Looking for a gift for yourself, a friend, or a loved one who has been diagnosed with cancer or they are a caregiver? Visit my shop. Thanks for joining us on today's episode of the Navigating Cancer TOGETHER podcast! If you enjoyed today's episode, please head over to iTunes and leave a rate and review to help me reach even more people that are facing cancer. Make sure you visit On the Other Side, follow me on Instagram, or sign up for my bi-weekly newsletter to get information and resources related to cancer. --- Send in a voice message: https://anchor.fm/navigatingcancertogether/message Support this podcast: https://anchor.fm/navigatingcancertogether/support

莫德納純素，輝瑞有蛋？ 這個台灣事實查核中心很努力在打疫苗假消息，近來疫苗假消息滿天飛，大家可多多利用。他們會找很多專家澄清，最近也會來問我的意見。疫苗假消息會讓廣大人群猶豫於施打疫苗，需要大家一起努力破除，推廣正確疫苗衛教！ https://tfc-taiwan.org.tw/taxonomy/term/475 這題是我傳給他們希望能寫一篇的。上週收到網友詢問我疫苗葷素的問題，看到莫德納純素，輝瑞有蛋我都快暈死了.... 我還豬肉滿福堡加蛋哩@@ 這些疫苗主要都是病毒的DNA/RNA/外殼所製成。病毒是植物還是動物？都不是，病毒就是病毒，病毒是僅能在生物體活細胞內複製繁衍的亞顯微病原體，它由一個核酸分子（DNA或RNA）與蛋白質構成非細胞形態，為類生物，無法自行表現出生命現象，靠寄生生活，是介於生命體及非生命體之間的有機物種，既不是生物亦不是非生物。當然也無動植物之分。 【錯誤】網傳「美國同修調查疫苗成分...莫德納純素...輝瑞有蛋」、「佛弟子請打mRNA疫苗」、「林藥師的說明...Moderna，輝瑞/BNT茹素者皆可打」？ https://tfc-taiwan.org.tw/articles/5962 經查： 一、佛教組織指出，並未聽聞疫苗有分葷素的說法。 二、關於傳言宣稱「AZ疫苗使用的腺病毒來自黑猩猩」，專家指出，AZ疫苗採用的是「會感染黑猩猩的病毒」，但這是「病毒」，不是黑猩猩，也不是黑猩猩身上的成分。 三、專家指出，現在的輝瑞、莫德納、AZ、嬌生疫苗成分，除了主成分的病毒mRNA、腺病毒重組DNA載體外，其餘化合物成分在動物、植物裡都有，無法從中判斷疫苗是否有動物成分。 四、專家指出，輝瑞疫苗沒有蛋的成分。 五、專家指出，AZ疫苗的腺病毒不會自我複製，與傳統「減活疫苗」不同，不是「減活疫苗」。 六、專家指出，關於傳言宣稱「使用胎牛血清」的疫苗，此為印度的國產疫苗「Covaxin」，此疫苗並未進口台灣。 因此，傳言為「錯誤」訊息。 給長輩的AZ疫苗懶人包 https://linshibi.com/?p=39590 高端 聯亞 國產疫苗懶人包 第二期結束就緊急授權可行嗎？ https://linshibi.com/?p=39547 新冠快篩懶人包 普篩 抗體快篩 抗原快篩 https://linshibi.com/?p=36564 新冠肺炎疫情下的防疫須知 常見問題解答FAQ https://linshibi.com/?p=35408 新冠疫苗常見問題懶人包 https://linshibi.com/?p=38945 林氏璧醫師的電子名片 https://lit.link/linshibi 歡迎贊助我喝咖啡 https://pay.firstory.me/user/linshibi Powered by Firstory Hosting

Today I am joined by Stefan and Kristian all the way from the land down under, Australia. We talk lockdowns, joblessness, UN troops on the streets, fluoride, cross-breeding DNA/RNA and so much more. Tune in!

伯恩本科毕业于四川大学测控技术与仪器专业，在校连续三次获得国家奖学金，还曾获宝钢优秀学生奖.。硕士研究生毕业于天津大学仪器科学与技术专业，获硕士研究生国家奖学金及蒋震奖学金。博士毕业于新加坡南洋理工大学，获得生物医学工程博士学位，后在加州理工学院从事博士后研究，独立完成, 类组织病理(histology-like)光声显微成像技术研究, 利用DNA和RNA对紫外光谱有很 好的吸收这一特点, 能够很好地实现媲美组织切片的细胞级(～0.32 μm)光声显微成像, 可以在术 中快速区分骨瘤的正常细胞与肿瘤细胞。

伯恩本科毕业于四川大学测控技术与仪器专业，在校连续三次获得国家奖学金，还曾获宝钢优秀学生奖.。硕士研究生毕业于天津大学仪器科学与技术专业，获硕士研究生国家奖学金及蒋震奖学金。博士毕业于新加坡南洋理工大学，获得生物医学工程博士学位，后在加州理工学院从事博士后研究，独立完成, 类组织病理(histology-like)光声显微成像技术研究, 利用DNA和RNA对紫外光谱有很 好的吸收这一特点, 能够很好地实现媲美组织切片的细胞级(～0.32 μm)光声显微成像, 可以在术 中快速区分骨瘤的正常细胞与肿瘤细胞。

伯恩本科毕业于四川大学测控技术与仪器专业，在校连续三次获得国家奖学金，还曾获宝钢优秀学生奖.。硕士研究生毕业于天津大学仪器科学与技术专业，获硕士研究生国家奖学金及蒋震奖学金。博士毕业于新加坡南洋理工大学，获得生物医学工程博士学位，后在加州理工学院从事博士后研究，独立完成, 类组织病理(histology-like)光声显微成像技术研究, 利用DNA和RNA对紫外光谱有很 好的吸收这一特点, 能够很好地实现媲美组织切片的细胞级(～0.32 μm)光声显微成像, 可以在术 中快速区分骨瘤的正常细胞与肿瘤细胞。

伯恩本科毕业于四川大学测控技术与仪器专业，在校连续三次获得国家奖学金，还曾获宝钢优秀学生奖.。硕士研究生毕业于天津大学仪器科学与技术专业，获硕士研究生国家奖学金及蒋震奖学金。博士毕业于新加坡南洋理工大学，获得生物医学工程博士学位，后在加州理工学院从事博士后研究，独立完成, 类组织病理(histology-like)光声显微成像技术研究, 利用DNA和RNA对紫外光谱有很 好的吸收这一特点, 能够很好地实现媲美组织切片的细胞级(～0.32 μm)光声显微成像, 可以在术 中快速区分骨瘤的正常细胞与肿瘤细胞。

伯恩本科毕业于四川大学测控技术与仪器专业，在校连续三次获得国家奖学金，还曾获宝钢优秀学生奖.。硕士研究生毕业于天津大学仪器科学与技术专业，获硕士研究生国家奖学金及蒋震奖学金。博士毕业于新加坡南洋理工大学，获得生物医学工程博士学位，后在加州理工学院从事博士后研究，独立完成, 类组织病理(histology-like)光声显微成像技术研究, 利用DNA和RNA对紫外光谱有很 好的吸收这一特点, 能够很好地实现媲美组织切片的细胞级(～0.32 μm)光声显微成像, 可以在术 中快速区分骨瘤的正常细胞与肿瘤细胞。

伯恩本科毕业于四川大学测控技术与仪器专业，在校连续三次获得国家奖学金，还曾获宝钢优秀学生奖.。硕士研究生毕业于天津大学仪器科学与技术专业，获硕士研究生国家奖学金及蒋震奖学金。博士毕业于新加坡南洋理工大学，获得生物医学工程博士学位，后在加州理工学院从事博士后研究，独立完成, 类组织病理(histology-like)光声显微成像技术研究, 利用DNA和RNA对紫外光谱有很 好的吸收这一特点, 能够很好地实现媲美组织切片的细胞级(～0.32 μm)光声显微成像, 可以在术 中快速区分骨瘤的正常细胞与肿瘤细胞。

伯恩本科毕业于四川大学测控技术与仪器专业，在校连续三次获得国家奖学金，还曾获宝钢优秀学生奖.。硕士研究生毕业于天津大学仪器科学与技术专业，获硕士研究生国家奖学金及蒋震奖学金。博士毕业于新加坡南洋理工大学，获得生物医学工程博士学位，后在加州理工学院从事博士后研究，独立完成, 类组织病理(histology-like)光声显微成像技术研究, 利用DNA和RNA对紫外光谱有很 好的吸收这一特点, 能够很好地实现媲美组织切片的细胞级(～0.32 μm)光声显微成像, 可以在术 中快速区分骨瘤的正常细胞与肿瘤细胞。

伯恩本科毕业于四川大学测控技术与仪器专业，在校连续三次获得国家奖学金，还曾获宝钢优秀学生奖.。硕士研究生毕业于天津大学仪器科学与技术专业，获硕士研究生国家奖学金及蒋震奖学金。博士毕业于新加坡南洋理工大学，获得生物医学工程博士学位，后在加州理工学院从事博士后研究，独立完成, 类组织病理(histology-like)光声显微成像技术研究, 利用DNA和RNA对紫外光谱有很 好的吸收这一特点, 能够很好地实现媲美组织切片的细胞级(～0.32 μm)光声显微成像, 可以在术 中快速区分骨瘤的正常细胞与肿瘤细胞。

伯恩本科毕业于四川大学测控技术与仪器专业，在校连续三次获得国家奖学金，还曾获宝钢优秀学生奖.。硕士研究生毕业于天津大学仪器科学与技术专业，获硕士研究生国家奖学金及蒋震奖学金。博士毕业于新加坡南洋理工大学，获得生物医学工程博士学位，后在加州理工学院从事博士后研究，独立完成, 类组织病理(histology-like)光声显微成像技术研究, 利用DNA和RNA对紫外光谱有很 好的吸收这一特点, 能够很好地实现媲美组织切片的细胞级(～0.32 μm)光声显微成像, 可以在术 中快速区分骨瘤的正常细胞与肿瘤细胞。

伯恩本科毕业于四川大学测控技术与仪器专业，在校连续三次获得国家奖学金，还曾获宝钢优秀学生奖.。硕士研究生毕业于天津大学仪器科学与技术专业，获硕士研究生国家奖学金及蒋震奖学金。博士毕业于新加坡南洋理工大学，获得生物医学工程博士学位，后在加州理工学院从事博士后研究，独立完成, 类组织病理(histology-like)光声显微成像技术研究, 利用DNA和RNA对紫外光谱有很 好的吸收这一特点, 能够很好地实现媲美组织切片的细胞级(～0.32 μm)光声显微成像, 可以在术 中快速区分骨瘤的正常细胞与肿瘤细胞。

(Content heavy!) Transcription, Structural Differences of Nucleic Acids, mRNA Processing, and RNA Interference

伯恩本科毕业于四川大学测控技术与仪器专业，在校连续三次获得国家奖学金，还曾获宝钢优秀学生奖.。硕士研究生毕业于天津大学仪器科学与技术专业，获硕士研究生国家奖学金及蒋震奖学金。博士毕业于新加坡南洋理工大学，获得生物医学工程博士学位，后在加州理工学院从事博士后研究，独立完成, 类组织病理(histology-like)光声显微成像技术研究, 利用DNA和RNA对紫外光谱有很 好的吸收这一特点, 能够很好地实现媲美组织切片的细胞级(～0.32 μm)光声显微成像, 可以在术 中快速区分骨瘤的正常细胞与肿瘤细胞。

伯恩本科毕业于四川大学测控技术与仪器专业，在校连续三次获得国家奖学金，还曾获宝钢优秀学生奖.。硕士研究生毕业于天津大学仪器科学与技术专业，获硕士研究生国家奖学金及蒋震奖学金。博士毕业于新加坡南洋理工大学，获得生物医学工程博士学位，后在加州理工学院从事博士后研究，独立完成, 类组织病理(histology-like)光声显微成像技术研究, 利用DNA和RNA对紫外光谱有很 好的吸收这一特点, 能够很好地实现媲美组织切片的细胞级(～0.32 μm)光声显微成像, 可以在术 中快速区分骨瘤的正常细胞与肿瘤细胞。

伯恩本科毕业于四川大学测控技术与仪器专业，在校连续三次获得国家奖学金，还曾获宝钢优秀学生奖.。硕士研究生毕业于天津大学仪器科学与技术专业，获硕士研究生国家奖学金及蒋震奖学金。博士毕业于新加坡南洋理工大学，获得生物医学工程博士学位，后在加州理工学院从事博士后研究，独立完成, 类组织病理(histology-like)光声显微成像技术研究, 利用DNA和RNA对紫外光谱有很 好的吸收这一特点, 能够很好地实现媲美组织切片的细胞级(～0.32 μm)光声显微成像, 可以在术 中快速区分骨瘤的正常细胞与肿瘤细胞。

伯恩本科毕业于四川大学测控技术与仪器专业，在校连续三次获得国家奖学金，还曾获宝钢优秀学生奖.。硕士研究生毕业于天津大学仪器科学与技术专业，获硕士研究生国家奖学金及蒋震奖学金。博士毕业于新加坡南洋理工大学，获得生物医学工程博士学位，后在加州理工学院从事博士后研究，独立完成, 类组织病理(histology-like)光声显微成像技术研究, 利用DNA和RNA对紫外光谱有很 好的吸收这一特点, 能够很好地实现媲美组织切片的细胞级(～0.32 μm)光声显微成像, 可以在术 中快速区分骨瘤的正常细胞与肿瘤细胞。

ISH 原位杂交In situ hybridization 英 [haɪbrɪdaɪˈzeɪʃn] 美 [haɪbrɪdəˈzeɪʃn]利用核酸分子单链之间有互补的碱基序列，将有放射性或非放射性的外源核酸(即探针)与组织、细胞或染色体上待测DNA或RNA互补配对，结合成专一的核酸杂交分子，经一定的检测手段将待测核酸在组织、细胞或染色体上的位置显示出来。为显示特定的核酸序列必须具备3个重要条件：组织、细胞或染色体的固定、具有能与特定片段互补的核苷酸序列(即探针)、有与探针结合的标记物。

ISH 原位杂交In situ hybridization 英 [haɪbrɪdaɪˈzeɪʃn] 美 [haɪbrɪdəˈzeɪʃn]利用核酸分子单链之间有互补的碱基序列，将有放射性或非放射性的外源核酸(即探针)与组织、细胞或染色体上待测DNA或RNA互补配对，结合成专一的核酸杂交分子，经一定的检测手段将待测核酸在组织、细胞或染色体上的位置显示出来。为显示特定的核酸序列必须具备3个重要条件：组织、细胞或染色体的固定、具有能与特定片段互补的核苷酸序列(即探针)、有与探针结合的标记物。

Emma looks at DNA and RNA and their function in the cells of living organisms. Ideal for preparing you for your High School Biology Exam. Click here for the full course, or visit this link: http://bit.ly/35WuyZy

Steve Bannon, Jason Miller, and Raheem Kassam are joined in studio by biological weapons expert Dr. Steven Hatfill to discuss the press conference announcements made by the CDC and HHS. The team also discusses the India study that found curious elements in the DNA/RNA sequences of the coronavirus.

Steve Bannon, Jason Miller, and Raheem Kassam are joined in studio by biological weapons expert Dr. Steven Hatfill to discuss the press conference announcements made by the CDC and HHS. The team also discusses the India study that found curious elements in the DNA/RNA sequences of the coronavirus.

This Friday's Topic is the 5th installment in the Self-Construction Block of podcasts and will focus on the topic: Visualizing a Long-Term Plan for Your Life. This dialogue will go in depth with our interview to understand the great value in being able to see beyond the short-term and form habits that foster success in the long-term picture.  This Friday's Guest is David Nathan MS.  David is a first generation American born Ghanaian American. On both his maternal and paternal sides, he is among the first generation to be born in the United States of America. David born in Oklahoma but raised in Mobile, AL where he played football starting from the age of six and soccer since the age of four. David enjoys working out, running, writing poetry, writing songs, and is a writing and recording artist. Growing up in a single parent home in the southern Alabama, David knows and has experienced the institutionally biased realities and hostile racial climate minorities are exposed to in America. David graduated from Xavier University of Louisiana in 2016 earning a Bachelor of Science in Biology and a Minor in Chemistry and conducted research on Hereditary Spastic Paraplegia via KIF5A point mutations. KIF5A is a neuronal kinesin which is a molecular motor protein that is responsible for carrying cellular cargo such as mitochondria or other cell organelles. David earned his Masters in Biomedical Science from Charles R. Drew University of Medicine and Science in 2018. He has an interest in substance abuse prevention and preventive medicine and his thesis for his master is titled: ELECTRONIC CIGARETTES EXACERBATE WESTERN DIET INDUCED HEPATIC STEATOSIS: ROLE OF CYP450 FAMILY OF PROTEINS AND ALTERED LIPID METABOLISM. David presented the work from his thesis at the 2019 Western Medical Research Conference in Carmel, CA in January of 2019  and received the subspecialty award in Endocrinology.  David aspires to become a physician and help fight health disparities everywhere. Since a young age, David has always had an interest in the biological sciences since starting elementary school. His interest stems from his perspective of seeing intelligent design in coding (DNA/RNA), form (proteins/cells/tissue), and function (organs/organ systems/organism) that point toward a highly intelligent creator. David plans to continue to refine and use all his talents to help, serve, and enlighten others for a lifetime. --- Support this podcast: https://anchor.fm/theliberatorspodcast/support